- Home
- PRZO vs ONCO Comparison
PRZO vs ONCO Comparison
Compare PRZO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | ONCO |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1M | 4.3M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PRZO | ONCO |
|---|---|---|
| Price | $1.15 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 415.3K | 40.3K |
| Earning Date | 08-28-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,007,440.00 | ★ $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 80.42 | N/A |
| 52 Week Low | $0.53 | $1.88 |
| 52 Week High | $3.16 | $179.35 |
Technical Indicators
Market Signals| Indicator | PRZO | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 37.19 |
| Support Level | $1.13 | $2.53 |
| Resistance Level | $1.51 | $2.13 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 3.06 | 11.59 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.